<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440553/" ref="ordinalpos=724&amp;ncbi_uid=5131764&amp;link_uid=PMC3440553" image-link="/pmc/articles/PMC3440553/figure/F1/" class="imagepopup">Figure 1. TOR <span class="highlight" style="background-color:">signaling</span> and cardiomyopathy.  From: TOR-based therapy for cardiomyopathy: evidence from zebrafish and human studies. </a></div><br /><div class="p4l_captionBody"><b>A)</b> Schematic of TOR signaling. TOR responds to growth factors via the PI3K-TSC-RheB signaling pathway, to nutrients via RAG GTPase, and to energy via AMPK. TOR regulates downstream cellular events including protein synthesis and autophagy. <b>B)</b> Partial inhibition of TOR signaling via rapamycin attenuates cardiomyopathy, which can be pursued as a new therapeutic strategy.</div></div>